Eccogene
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 DiabetesHeart FailureChronic Kidney Disease | |
| Phase 2 | Thyroid hormone receptor beta (THRβ) | ObesityMASH / NASH |
Upcoming events
(10 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
2028 (7)
April 2028 (1)
Est. primary completion 2028-04-06 · NCT07775404 · CT.gov ↗
What to watch
May 2028 (2)
July 2028 (4)
2029 (1)
September 2029 (1)
elecoglipronPhase 3Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Est. primary completion 2029-09-03 · NCT07761117 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Est. primary completion 2030-10-04 · NCT07753993 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.